Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
Natalia Fluder, Morgane Humbel, Emeline Recazens, Alexis A. Jourdain, Camillo Ribi, George Tsokos, Denis Comte
Natalia Fluder, Morgane Humbel, Emeline Recazens, Alexis A. Jourdain, Camillo Ribi, George Tsokos, Denis Comte
View: Text | PDF
Research Article Immunology

Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus

  • Text
  • PDF
Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and widespread inflammation. NK cells display marked functional impairment in SLE, including defective cytotoxicity and cytokine production, but the underlying mechanisms remain poorly defined. Here, we show that mitochondrial dysfunction and impaired mitophagy are key contributors to NK cell abnormalities in SLE. Using complementary structural, metabolic, and proteomic analyses, we found that SLE NK cells accumulate enlarged and dysfunctional mitochondria, exhibit impaired lysosomal acidification, and release mitochondrial DNA into the cytosol — features consistent with defective mitochondrial quality control. Transcriptional and proteomic profiling revealed downregulation of key mitophagy-related genes and pathways. These abnormalities correlated with reduced NK cell degranulation and cytokine production. We then tested whether enhancing mitochondrial quality control could restore NK cell function. The mitophagy activator Urolithin A improved mitochondrial and lysosomal parameters and rescued NK cell effector responses in vitro. Hydroxychloroquine partially restored mitochondrial recycling and reduced cytosolic mtDNA. These findings suggest that defective mitophagy and mitochondrial dysfunction are major contributors to NK cell impairment in SLE and that targeting mitochondrial quality control may represent a promising strategy for restoring immune balance in this disease.

Authors

Natalia Fluder, Morgane Humbel, Emeline Recazens, Alexis A. Jourdain, Camillo Ribi, George Tsokos, Denis Comte

×

Figure 2

Defective lysosomal acidification drives mitochondrial dysfunction in SLE NK cells.

Options: View larger image (or click on image) Download as PowerPoint
Defective lysosomal acidification drives mitochondrial dysfunction in SL...
(A) LC-MS–based proteomic analysis of NK cells isolated from healthy controls (HC, n = 4) and patients with SLE (n = 4). Volcano plot showing differentially expressed proteins in SLE versus HC NK cells (log2 fold change > 0.5 or < –0.5). (B) Selected significantly upregulated (red) and downregulated (blue) proteins in SLE NK cells (P < 0.05). (C) Gene ontology enrichment analysis of differentially expressed proteins. (D and E) Lysosomal number (D) and lysosomal pH (E, left panel) in NK cells from patients with SLE and HC assessed by flow cytometry using LysoTracker and LysoSensor probes, respectively. (E, right panel) Lysosomal pH stratified by disease activity score (SLEDAI). (F) Ratio of LysoTracker to LysoSensor fluorescence intensity in NK cells from patients with SLE and HC. *P < 0.05 and **P < 0.01 by Wilcoxon test (D and F) or mixed-effects analysis (E). (G and H) NK cells from HC were activated overnight in the presence or absence of bafilomycin A1 (100 nM) or subjected to starvation. Mitochondrial mass (G) and lysosomal number (H) were assessed by flow cytometry. Mitochondrial mass was analyzed using the Wilcoxon signed-rank test. Lysosomal number was analyzed using the Friedman test followed by Wilcoxon signed-rank post hoc tests. *P < 0.05, **P < 0.001. (I) NK cells from HC (n = 11) were activated overnight with or without bafilomycin A1 (100 nM) and fractionated into whole-cell extract (WCE), cytosolic, and mitochondrial fractions. Cytosolic mtDNA abundance was quantified by qPCR using ND2 and D-loop regions. Data are expressed as fold change in bafilomycin-treated cells relative to untreated HC samples. A log2 fold change > 0.5 or < –0.5 was considered significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts